Cited by 176Bariatric Surgery and OutcomesRegulation of Appetite and ObesityGastrointestinal motility and disorders

Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation

le Roux, Carel W., Borg, Cynthia, Wallis, Katharina, Vincent, Royce P., Bueter, Marco, Goodlad, Robert, Ghatei, Mohammed A., Patel, Ameet +2 more·2010·Annals of Surgery

Abstract

OBJECTIVE: We aimed to determine changes in crypt cell proliferation and glucagon-like peptide-2 (GLP-2) in rodents and man after Roux-en-Y gastric bypass (RYGB). SUMMARY OF BACKGROUND DATA: Roux-en-Y gastric bypass results in sustained weight loss and reduced appetite with only mild gastrointestinal side effects. Glucagon-like peptide-2 released from intestinal l-cells after nutrient intake stimulates intestinal crypt cell proliferation and mitigates the effects of gut injury. METHODS: Wistar rats underwent either RYGB (n = 6) or sham procedure (n = 6) and plasma GLP-2, GLP-1, and gut hormone peptide YY (PYY) were measured after 23 days. Biopsies from the terminal ileum were stained using the antibody to Ki67, which detects cyclins and hence demonstrates cells in the S-phase of the cell cycle. The total number of cells, number of mitosis, and number of labeled cells per crypt were counted. Obese patients (n = 6) undergoing RYGB were evaluated following a 420 kcal meal preoperatively, and 1, 3, 6, 12, and 24 months later for responses in l-cell products such as GLP-2, GLP-1, total PYY, and PYY3-36. RESULTS: Rat GLP-2 levels after RYGB were elevated 91% above sham animals (P = 0.02). At necropsy, mitotic rate (P < 0.001) and cells positive for the antibody Ki67 (P < 0.001) were increased, indicating crypt cell proliferation. Human GLP-2 after RYGB reached a peak at 6 months of 168% (P < 0.01) above preoperative values. Area under the curve for GLP-1 (P < 0.0001), total PYY (P < 0.01), and PYY3-36 (P < 0.05) responses increased progressively over 24 months. CONCLUSIONS: RYGB leads to increased GLP-2 and mucosal crypt cell proliferation. Other gut hormones from l-cells remain elevated for at least 2 years in humans. These findings may account for the restoration of the absorptive surface area of the gut, which limits malabsorption and contributes to the long-term weight loss after RYGB.

Integrity signals

Registry

Crossref · 10.1097/sla.0b013e3181d3d21f

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Altered gut barrier function through either reduced bowel permeability from chronically increased secretion of GLP-2 or shifts in the intestinal microflora after surgery may be a second factor in the reductions in endotoxemia/inflammation after bariatric surgery.

    “A second factor may be the altered gut barrier function through either reduced bowel permeability from chronically increased secretion of GLP-2 or shifts in the intestinal microflora after surgery [130-132].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
le Roux, C. W., Borg, C., Wallis, K., Vincent, R. P., Bueter, M., Goodlad, R., Ghatei, M. A., Patel, A., Bloom, S. R., & Aylwin, S. J. B.
Affiliations
  • King's College Hospital (GB)
  • Imperial College London (GB)
  • Institute of Cancer Research (GB)
  • King's College London (GB)
Corresponding author
  • Wallis, Katharina
  • Vincent, Royce P.
  • Bueter, Marco
  • Ghatei, Mohammed A.
  • Bloom, Stephen R.
Venue
Annals of Surgery
Published
2010-07
Volume
252
Issue
1
Pages
50-56
ISSN
0003-4932 (ISSN-L)
OpenAlex
W1972517166
Cited by
176
References
42
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 10 · 2019: 12 · 2018: 16 · 2017: 12 · 2016: 24 · 2015: 20 · 2014: 9 · 2013: 17 · 2012: 9
FWCI
12.88
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Wellcome Trust
  • National Institute for Health and Care Research (NF-SI-0507-10337)
  • Biotechnology and Biological Sciences Research Council (BB/E52708X/1)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
Roux-en-Y gastric bypass, gastric bypass, glucagon-like peptide-2, glucagon-like peptide-1, peptide YY, PYY3-36, intestinal L cells, gastrointestinal hormones, Ki-67, terminal ileum, malabsorption, weight loss, bariatric surgery, rat model
MeSH terms
Adult, Animals, Female, Humans, Ileum, Intestinal Mucosa, Male, Middle Aged, Mitosis, Gastric Bypass, Rats, Wistar, Rats, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review